Much of the inter-individual variability in drug efficacy and risk of adverse reactions is due to
polymorphisms in genes encoding proteins involved in drug pharmacokinetics and …

Using pharmacogenetics in guiding drug therapy experiences a steady increase in uptake,
although still leads to discussions as to its clinical use. Psychiatry constitutes a field where …

Aim: We evaluated healthcare practitioners' perspectives regarding clinical
pharmacogenetics in Cairo, Egypt. Materials & methods: We administered a paper-based …

Pharmacogenomics (PGx) relates to the study of genetic factors determining variability in
drug response. Implementing PGx testing in paediatric patients can enhance drug safety …

The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug
exposure and patient genetics. The purpose of this analysis was to expand on a previous …

Background: Pharmacogenetics has a potential for optimizing drug response and identifying
risk of toxicity for patients. Pharmacogenetics knowledge of healthcare professionals and the …

The goal of pharmacogenomic research is to discover and validate genetic variants that are
predictive of drug response, for eventual implementation into clinical practice. Cancer …

Cytochromes are proteins that catalyze electron transfer reactions of well-known metabolic
pathways and are classified in various superfamilies. The CYP, or P450, superfamily …

Heparin is a natural agent with antithrombotic action, commercially available for therapeutic
use as unfractionated heparin and low molecular weight heparin. Heparin-induced …

Background: Clinically relevant polymorphisms often demonstrate population-specific allele
frequencies. Central and South America remain largely uncategorized in the context of …